Mean (SD) systemic exposures of bevacizumab, ranibizumab and aflibercept
| Geometric mean ratio | |||||
|---|---|---|---|---|---|
| Bevacizumab | Ranibizumab | Aflibercept | Bevacizumab/ ranibizumab (95% CI) | Aflibercept/ ranibizumab (95% CI) | |
| First dose | |||||
| Cmax, nM | 0.76 (0.31) n=15 | 0.11 (0.13) n=20 | 0.45 (0.29) n=21 | 8.80 (5.59 to 13.8) | 4.65 (3.07 to 7.05) |
| Cmin, nM | 0.44 (0.14) n=14 | 0.002 (0.002) n=19 | 0.05 (0.02) n=20 | 310 (188 to 511) | 37.3 (23.7 to 58.7) |
| AUC0–28, nM*h | 15.73 (5.76) n=14 | 0.46 (0.24) n=19 | 4.32 (1.77) n=20 | 34.9 (26.4 to 46.1) | 9.49 (7.4 to 12.2) |
| Third dose | |||||
| Cmax, nM | 1.47 (0.55) n=15 | 0.07 (0.05) n=18 | 0.58 (0.52) n=21 | 22.7 (14.8 to 34.8) | 7.28 (4.91 to 10.8) |
| Cmin, nM | 0.70 (0.29) n=14 | 0.002 (0.002) n=18 | 0.07 (0.03) n=21 | 500 (304 to 822) | 52.9 (33.8 to 82.8) |
| AUC60–88, nM*h | 29.12 (10.35) n=14 | 0.41 (0.17) n=18 | 5.38 (1.77) n=21 | 72.4 (55.4 to 94.8) | 13.5 (10.6 to 17.3) |
AUC, area under curve; Cmax, maximum serum concentration; Cmin, minimum serum concentration.